BMCMI
IART icon

Bryn Mawr Capital Management Inc’s Integra LifeSciences IART Stock Holding History

Bryn Mawr Capital Management Inc’s Portfolio IART Stock Details IART Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-24,401
Closed -$459K – 614
2014
Q1 		$459K Buy
+24,401
New +$471K 0.04% 378

Other funds holding IART

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VNIM
Vaughan Nelson Investment Management Houston, Texas $11.3B AUM 53% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
EIP
Epoch Investment Partners New York $16.5B AUM 24.3% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Bryn Mawr Capital Management Inc's IART Position: Q2 2014 in Review

Bryn Mawr Capital Management Inc sold out of Integra LifeSciences (IART) in Q2 2014, closing a stake of 24,401 shares — an estimated $459K sold.

Bryn Mawr Capital Management Inc first reported a position in IART in Q1 2014 and held it in 1 quarter. The position peaked at $459K in Q1 2014. 147 funds tracked by Wall St. Rank hold IART as of Q2 2014.

  • Bryn Mawr Capital Management Inc reported no remaining Integra LifeSciences position as of Q2 2014 after selling out during the quarter.
  • Bryn Mawr Capital Management Inc sold 24,401 Integra LifeSciences shares in Q2 2014, an estimated $459K.
  • Bryn Mawr Capital Management Inc first reported a position in Integra LifeSciences in Q1 2014 and held it in 1 quarter.
  • Bryn Mawr Capital Management Inc's Integra LifeSciences position peaked at $459K in Q1 2014.
  • 147 funds tracked by Wall St. Rank held Integra LifeSciences as of Q2 2014.

Based on Bryn Mawr Capital Management Inc's 13F filing for Q2 2014, filed 13 Aug 2014.